An observational study in Obesity, Morbid, Metabolic Syndrome and Bariatric Surgery Candidate, sponsored by Aleris Hospital. Active, not recruiting at 1 site in Norway. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-02-06.
Sponsored by Aleris Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies in Obesity, Morbid with a site in Norway — 22 open to participants now, 26 under way, none of them phase 3. Obesity, Morbid · Norway.
Among the 51 studies in Obesity, Morbid with a site in Norway, this one has the largest planned enrollment of the 30 observational ones that give a count, is the only one that started in 2020, is one of 30 observational ones, reaches primary completion later than 23 of the 25 other live ones, and was the 49th registered.
941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.
Browse Obesity, Morbid studies →22 of the 51 studies in Obesity, Morbid with a site in Norway are open now. Recruiting first, the newest first:
Oslo University Hospital · Sites in Norway
Ages 20–60
Norwegian University of Science and Technology · Sites in Norway
Ages 18–70
Norwegian University of Science and Technology · Sites in Norway
Ages 18–70
Norwegian University of Science and Technology · Sites in Norway
Ages 18–70
Norwegian University of Science and Technology · Sites in Norway
Ages 18–70
A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →
Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 280 is above the median of 80 across 311 observational studies indexed under Obesity, Morbid.
Median enrollment 69 across the 21 interventional studies, 12 across the 30 observational. Of the 23 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 51 has an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Aleris Hospital as lead sponsor.
Aleris Hospital has 1 study filed under Obesity, Morbid — fewer than ten, so there is no comparison to draw.
6 of the studies in Obesity, Morbid with a site in Norway that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00626964The Hospital of VestfoldPrevention of Coronary Heart Disease in Morbidly Obese Patients | 2026-12 |
| NCT02767505Göteborg UniversityBypass Equipoise Sleeve Trial (BEST) | 2026-12 |
| NCT03448783Norwegian University of Science and TechnologyBariatric Surgery and Pharmacokinetics of Apixaban | 2026-12 |
| NCT03440177Norwegian University of Science and TechnologyBariatric Surgery and Pharmacokinetics of Ramipril | 2026-12 |
| NCT03449485Norwegian University of Science and TechnologyBariatric Surgery and Pharmacokinetics of Chlorprothixene | 2026-12 |
Add all 6 to your calendar (.ics) → With an account.
Among the 51 studies in Obesity, Morbid with a site in Norway, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main aim of this project is to assess the safety and efficiency of the SASI Bipartition.
The Roux-en-Y Gastric Bypass (RYGB) is the procedure of choice in morbid obesity with metabolic disorders in most of the reference centers. Recent data describes the SASI Bipartition as being as efficient on weight loss and co-morbidities as the RYGB, with the advantage of being less technically difficult and less morbidity. In order to draw definite conclusions regarding the procedure, larger series with longer follow-up are necessary.
Patients with BMI over 40, or with BMI over 35 with comorbidities are offered SASI Bipartition with 300 cm common limb or standard RYGB. Follow up is performed through visits at 3, 12, 24, 36, 48, and 60 months after surgery.
Results on weight loss, comorbidities resolution, complications, and need of supplements are registered.
All patients approved for bariatric surgery at Bariatric Clinic, Aleris Hospital, Norway
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects submitted to SASI Bipartition
Procedure: SASI Bipartition
Subjects submitted to gastric bypass
Procedure: Gastric bypass
SASI Bipartition is performed with a sleeve gastrectomy over a 32 French gastric bougie and a 300 cm common limb. Side-to-side gastroileostomy with a diameter of approximately 2.5 cm at the anterior part of antrum, 6 cm proximal to pylorus.
Also known as: Single-anastomosis Sleeve Ileal Bypass
A small gastric pouch (15 mL) is created, and the jejunum brought up as an antecolic and antegastric fashion. Routine limb lengths were 150 cm for the alimentary limb and 60 cm for the bilio-pancreatic limb. Both mesenteric defects are closed with the Endohernia® stapler.
Also known as: Roux-en-Y gastric bypass
Weight change
Measured as percent of Excess Weight Loss (%EWL) using the following formula: ((weight at each study visit - initial weight) / (initial weight - ideal weight)) X 100
Time frame: 3 to 60 months after surgery
Waist size change
Waist size (in cm)
Time frame: 3 to 60 months after surgery
Medical and surgical complication
According to Clavien-Dindo classification
Time frame: 3 to 60 months after surgery
Operative time
Expressed in minutes
Time frame: During surgery
Hemoglobin
Measurement of Hemoglobin will explore the nutritional status of patients. Results will be expressed in g/l
Time frame: before surgery up to 60 months after surgery
Albumin
Measurement of albumin will explore the nutritional status of patients. Results will be expressed in g/l
Time frame: before surgery up to 60 months after surgery
Ferritin
Measurement of ferritin will explore the nutritional status of patients. Results will be expressed in microg/l
Time frame: before surgery up to 60 months after surgery
Iron
Measurement of iron will explore the nutritional status of patients. Results will be expressed in micromol/l
Time frame: before surgery up to 60 months after surgery
Parathyroid hormone (PTH)
Measurement of PTH will explore the nutritional status of patients. Results will be expressed in pmol/L
Time frame: before surgery up to 60 months after surgery
Vitamin B12
Measurement of vitamin B12 will explore the nutritional status of patients. Results will be expressed in pmol/l
Time frame: before surgery up to 60 months after surgery
Vitamin D
Measurement of vitamin D will explore the nutritional status of patients. Results will be expressed in nmol/l
Time frame: before surgery up to 60 months after surgery
Fasting glycemia
Measurement of fasting glycemia will explore the Metabolic efficiency of surgery. Results will be expressed in mmol/l
Time frame: before surgery up to 60 months after surgery
HbA1c
Measurement of HbA1c will explore the Metabolic efficiency of surgery. Results will be expressed in %
Time frame: before surgery up to 60 months after surgery
Triglycerides
Measurement of triglycerides will explore the Metabolic of surgery. Results will be expressed in mmol/l
Time frame: before surgery up to 60 months after surgery
Cholesterol
Measurement of cholesterol will explore the Metabolic efficiency of surgery. Results will be expressed in mmol/l
Time frame: before surgery up to 60 months after surgery
HDL
Measurement of HDL will explore the Metabolic efficiency of surgery. Results will be expressed in mmol/l
Time frame: before surgery up to 60 months after surgery
LDL
Measurement of LDL will explore the Metabolic efficiency of surgery. Results will be expressed in mmol/l
Time frame: before surgery up to 60 months after surgery
Antidiabetic drugs
Evolution of antidiabetic drugs will explore the Metabolic efficiency of surgery. This outcome will be expressed in terms of increase, decrease, discontinuation or restart of treatment.
Time frame: 3 to 60 months after surgery
Antilipidemic drugs
Evolution of antilipidemic drugs will explore the Metabolic efficiency of surgery. This outcome will be expressed in terms of increase, decrease, discontinuation or restart of treatment.
Time frame: 3 to 60 months after surgery
Antihypertensive drugs
Evolution of antihypertensive drugs will explore the Metabolic efficiency of surgery. This outcome will be expressed in terms of increase, decrease, discontinuation or restart of treatment.
Time frame: 3 to 60 months after surgery
Use of Continuous Positive Airway Pressure for Obstructive Sleep Apnea (OSA)
Evolution of the use of Continuous Positive Airway Pressure will explore the Metabolic efficiency of surgery. This outcome will be expressed in terms of persistence or not of OSA.
Time frame: 3 to 60 months after surgery
Plan to share: Undecided — The results of the study will be published in a scientific journal.
Started Aug 2020 (actual). Primary completion is estimated for Jul 2027, 83 months after the start.
Of 138 non-industry observational studies under Obesity, Morbid, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 132. This study's planned 83 months is above that.
Counting every sponsor, half of 139 studies reached it within 46 months; a quarter within 16 and three quarters within 132.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.